Tecentriq is a type of immunotherapy called an “immune checkpoint inhibitor.”

Tecentriq (chemical name: atezolizumab) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in March 2019 to be used in combination with the chemotherapy medicine Abraxane (chemical name: albumin-bound or nab-paclitaxel) to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.

On Aug. 27, 2021, Genentech — the company that makes Tecentriq — voluntarily withdrew the breast cancer indication from Tecentriq in the United States. People in the United States who are receiving Tecentriq infusions for advanced-stage triple-negative breast cancer may continue this treatment, but should discuss other treatment options with their doctors.

The withdrawal only applies to breast cancer treatment in the United States and doesn’t affect other approved indications for Tecentriq. The withdrawal also doesn’t affect other countries’ approval of Tecentriq to treat metastatic PD-L1-positive breast cancer.

If you or your doctor have questions or concerns about Tecentriq coverage, reimbursement, or out-of-pocket costs, please call the Genentech Patient Resource Center at 877-436-3683 for help.


How Tecentriq works

Tecentriq is a type of immunotherapy called an “immune checkpoint inhibitor.” Immune checkpoints are proteins in your body that help your immune system tell the difference between your own cells and foreign invaders, such as harmful bacteria. Cancer cells sometimes find ways to use these immune checkpoint proteins as a shield to avoid being identified and attacked by the immune system.

Immune checkpoint inhibitors target these immune checkpoint proteins and help the immune system recognize and attack cancer cells. PD-1 is a type of checkpoint protein found on T cells, which are immune system cells that roam throughout the body looking for signs of disease or infection. PD-L1 is another checkpoint protein found on many healthy cells in the body. When PD-1 binds to PD-L1, it stops T cells from killing a cell.

Still, some cancer cells have a lot of PD-L1 on their surface, which stops T cells from killing these cancer cells. An immune checkpoint inhibitor medicine that stops PD-1 from binding to PD-L1 allows T cells to attack the cancer cells.

Learn more about immune checkpoint inhibitors and how they work


What to expect when taking Tecentriq

Tecentriq is given intravenously, which means the medicine is delivered directly into your bloodstream through an IV or a port.

You get Tecentriq on a 28-day cycle. On days 1 and 15, you get Tecentriq followed by Abraxane, which is also given intravenously. On day 8, you get Abraxane alone.

Women who are pregnant or planning to get pregnant should not be given Tecentriq. Tecentriq can cause embryo death and birth defects. It’s important that you don’t get pregnant while you’re getting Tecentriq; you must use effective birth control.


Tecentriq side effects

The most common side effects of Tecentriq are:

Tecentriq also can cause other serious side effects, including:

  • Lung problems

  • Liver problems

  • Colitis (inflammation of the inner lining of the colon): Symptoms include diarrhea, blood or mucus in your stool, and severe stomach pain.

  • Hormone gland problems: Tecentriq may affect glands that make hormones your body needs to function properly, including the thyroid, adrenal glands, pancreas, and pituitary gland. Symptoms include headaches that won’t go away, extreme tiredness, weight gain or loss, changes in mood or behavior, feeling cold, and constipation.

  • Other organ problems: Tecentriq also may affect other organs in your body. Symptoms include severe muscle weakness, confusion, blurry or double vision, neck stiffness, skin blisters, irregular heartbeat, shortness of breath, or swelling of the ankles.

  • Severe infection: Symptoms include fever, cough, flu-like symptoms, pain when urinating, or back pain.


Tecentriq (atezolizumab) prescribing information. Genentech. San Francisco, CA. 2019. Available at

— Last updated on June 29, 2022, 3:09 PM

More from this topic
Other sections related to Tecentriq